Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma

  • Authors:
    • Haruhiko Inufusa
    • Toshiyuki Adachi
    • T. Kiyokawa
    • Yoshihiro Nakatani
    • Tsukasa Wakano
    • Masato Nakamura
    • Kiyotaka Okuno
    • Hitoshi Shiozaki
    • Shigeto Yamamoto
    • Motoyuki Suzuki
    • Osamu Ando
    • Masashi Kurimoto
    • Masayuki Miyake
    • Masayuki Yasutomi
  • View Affiliations

  • Published online on: November 1, 2001     https://doi.org/10.3892/ijo.19.5.941
  • Pages: 941-946
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor procoagulant is associated with cancer at advanced stages of malignancy such as infiltration and metastasis. In the present study, we investigated the role of Ley glycolipid in the mechanism of cancer metastasis. Ley glycolipid acts as an important cofactor in the expression of the blood-coagulating activity of cancer cell-derived coagulating activity 1 (CCA-1), which is one of the known tumor procoagulants. Monoclonal antibody (MoAb) FS01, which serves as the Ley-recognizing epitope, inhibits the procoagulant activity of CCA-1 was found to dose-dependently inhibit the procoagulant activity of normal plasma induced by the human lung adenocarcinoma cell line, HAL8, which shows a high level of Ley expression. It did not, however, inhibit the procoagulant activity of the human colon cancer cell line, RPMI4788, which does not express Ley. Administration of FS01 MoAb inhibited lung metastasis of HAL8 cells, but not that of RPMI4788. The absence of antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity of FS01 MoAb against the HAL8 cell line suggests that the inhibition of HAL8 metastasis by FS01 MoAb derives from the inhibition of blood-coagulating activity of the latter. These findings indicate that Ley glycolipid plays an important role in the mechanism of cancer metastasis via the procoagulant activity of CCA-1.

Related Articles

Journal Cover

November 2001
Volume 19 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Inufusa H, Adachi T, Kiyokawa T, Nakatani Y, Wakano T, Nakamura M, Okuno K, Shiozaki H, Yamamoto S, Suzuki M, Suzuki M, et al: Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma. Int J Oncol 19: 941-946, 2001
APA
Inufusa, H., Adachi, T., Kiyokawa, T., Nakatani, Y., Wakano, T., Nakamura, M. ... Yasutomi, M. (2001). Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma. International Journal of Oncology, 19, 941-946. https://doi.org/10.3892/ijo.19.5.941
MLA
Inufusa, H., Adachi, T., Kiyokawa, T., Nakatani, Y., Wakano, T., Nakamura, M., Okuno, K., Shiozaki, H., Yamamoto, S., Suzuki, M., Ando, O., Kurimoto, M., Miyake, M., Yasutomi, M."Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma". International Journal of Oncology 19.5 (2001): 941-946.
Chicago
Inufusa, H., Adachi, T., Kiyokawa, T., Nakatani, Y., Wakano, T., Nakamura, M., Okuno, K., Shiozaki, H., Yamamoto, S., Suzuki, M., Ando, O., Kurimoto, M., Miyake, M., Yasutomi, M."Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma". International Journal of Oncology 19, no. 5 (2001): 941-946. https://doi.org/10.3892/ijo.19.5.941